1. Home
  2. PHAT vs CRON Comparison

PHAT vs CRON Comparison

Compare PHAT & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • CRON
  • Stock Information
  • Founded
  • PHAT 2018
  • CRON N/A
  • Country
  • PHAT United States
  • CRON Canada
  • Employees
  • PHAT N/A
  • CRON N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • CRON Medicinal Chemicals and Botanical Products
  • Sector
  • PHAT Health Care
  • CRON Health Care
  • Exchange
  • PHAT Nasdaq
  • CRON Nasdaq
  • Market Cap
  • PHAT 769.0M
  • CRON 809.4M
  • IPO Year
  • PHAT 2019
  • CRON N/A
  • Fundamental
  • Price
  • PHAT $11.70
  • CRON $2.70
  • Analyst Decision
  • PHAT Strong Buy
  • CRON
  • Analyst Count
  • PHAT 5
  • CRON 0
  • Target Price
  • PHAT $16.40
  • CRON N/A
  • AVG Volume (30 Days)
  • PHAT 1.3M
  • CRON 3.0M
  • Earning Date
  • PHAT 11-06-2025
  • CRON 11-11-2025
  • Dividend Yield
  • PHAT N/A
  • CRON N/A
  • EPS Growth
  • PHAT N/A
  • CRON N/A
  • EPS
  • PHAT N/A
  • CRON 0.05
  • Revenue
  • PHAT $114,039,000.00
  • CRON $130,282,000.00
  • Revenue This Year
  • PHAT $213.11
  • CRON $19.67
  • Revenue Next Year
  • PHAT $91.84
  • CRON $30.56
  • P/E Ratio
  • PHAT N/A
  • CRON $56.17
  • Revenue Growth
  • PHAT 1049.82
  • CRON 28.01
  • 52 Week Low
  • PHAT $2.21
  • CRON $1.60
  • 52 Week High
  • PHAT $19.50
  • CRON $3.16
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 50.37
  • CRON 61.24
  • Support Level
  • PHAT $10.33
  • CRON $2.52
  • Resistance Level
  • PHAT $12.97
  • CRON $2.76
  • Average True Range (ATR)
  • PHAT 0.89
  • CRON 0.10
  • MACD
  • PHAT -0.11
  • CRON -0.01
  • Stochastic Oscillator
  • PHAT 45.41
  • CRON 68.33

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About CRON Cronos Group Inc. Common Share

Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

Share on Social Networks: